82791-93-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Trifluoromethyl-3H-benzoimidazole-5-carboxylic acid is utilized as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and properties contribute to the development of new drugs and treatments, particularly in the realm of medicinal chemistry where it may serve as a precursor to more complex molecules with therapeutic potential.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-Trifluoromethyl-3H-benzoimidazole-5-carboxylic acid is employed as a key component in the study and design of innovative drug candidates. Its presence in these compounds can influence their pharmacological properties, such as potency, selectivity, and bioavailability, making it a valuable asset in the advancement of new therapeutic agents.

Upstream product

• 619-05-6 3,4-diaminobenzoic acid 
• 36692-49-6 Methyl 3,4-diaminobenzoate 
• 76-05-1 trifluoroacetic acid 
• 291506-95-1 4-amino-3-(2,2,2-trifluoro-acetylamino)-benzoic acid ethyl ester 
• 1588-83-6 4-amino-3-nitrobenzoic acid 

Downstream Products

• 89457-09-0 ethyl 2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxylate 

Relevant academic research and scientific papers

BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA

Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY

A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune disorders, neurodege

TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS

A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

Efficient syntheses of 2-fluoroalkylbenzimidazoles and -benzothiazoles

We report an efficient one-step route to 2-fluoroalkylbenzimidazoles and -benzothiazoles via the condensation of fluorinated carboxylic acids and aromatic diamines or aminothiophenols. Additionally, we describe the syntheses of fluoroalkyl-azabenzimidazoles, -purines, and -imidazolopyrazines. This method is high-yielding with broad scope and is operationally simple with potential application to parallel synthesis.

Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives

This study evaluated the relationship between the physicochemical properties, membrane permeability and in vitro giardicidal activity of twenty nine benzimidazole derivatives (1-7n). The retention time data from reverse phase high performance chromatography (RP-HPLC) were used to estimate aqueous solubility and lipophilicity of these compounds. The apparent permeability was determined using Caco-2 cell monolayer. The calculation of some descriptors, such as Clog P, PSA, was performed using ACD labs software. For benzimidazole derivatives with NHCOOCH3, CH3, NH2, SH and SCH3 groups at the 2-position, a quadratic type of regression model was obtained with giardicidal activity and aqueous solubility or lipophilicity. On the other hand, giardicidal activity of 2-(trifluoromethyl)-1H-benzimidazole derivatives was influenced by lipophilicity, hydrogen bond donors and molecular volume but it was not determined by their apparent permeability in Caco-2 cell line.

Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives

Novel 4″-O-benzimidazolyl clarithromycin derivatives were designed, synthesized and evaluated for their in vitro antibacterial activities. These benzimidazolyl derivatives exhibited excellent activity against erythromycin-susceptible strains better than the references, and some of them showed greatly improved activity against erythromycin-resistant strains. Compounds 16 and 17, which have the terminal 2-(4-methylphenyl)benzimidazolyl and 2-(2-methoxyphenyl)benzimidazolyl groups on the C-4″ bishydrazide side chains, were the most active against erythromycin-resistant Staphylococcus pneumoniae expressing the erm gene and the mef gene. In addition, compound 17 exhibited the highest activity against erythromycin-susceptible S. pneumoniae ATCC49619 and Staphylococcus aureus ATCC25923 as well. It is worth noting that the 4″-O-(2-aryl)benzimidazolyl derivatives show higher activity against erythromycin-susceptible and erythromycin-resistant strains than the 4″-O-(2-alkyl)benzimidazolyl derivatives.

Rapid one-pot preparation of 2-substituted benzimidazoles from 2-nitroanilines using microwave conditions

A high yielding one-pot procedure for the generation of 2-substituted benzimidazoles directly from 2-nitroanilines by in situ reduction and cyclization using a microwave procedure is described.

Full length article

Cyclocondensation of N-(carbotrifluoromethyl)-ortho-arylenediamines leads to a series of 2-trifluoromethylarylimidazoles with good yields on montmorillonite K10 in 'dry media' under microwave irradiation within 2 min in a domestic oven. By conventional heating in the same conditions, no reaction is observed.

Novel β-lactam antibiotics

Antibacterially active and animal growth-promoting novel β-lactam compounds of the formula STR1 in which R1 represents the radical STR2 Y representing N or CR9, or Y--R7 representing >C=O or >C=N--R7, Z representing O, S, or NR10, and R2 represents hydrogen or a protective group.